Fill Finish Capability Pharmalucence operates a radiopharmaceutical manufacturing facility with a fully automated injectable filling line and cGMP readiness, enabling scalable fill-finish operations. The company has a proven track record as a contract manufacturer for imaging agents, including a past project with Lantheus to manufacture DEFINITY vials, demonstrating openness to new client engagements and process transfers. This combination makes Pharmalucence a strong candidate for radiopharma developers and hospitals seeking reliable supply security.

Proven CDMO Partnerships Past partnership with Lantheus to manufacture DEFINITY Vial demonstrates a proven CDMO capability and experience with process transfers and scale up. This history suggests the company can onboard new radiopharmaceutical programs efficiently and support customers through regulatory-ready manufacturing. Target opportunities include imaging agent developers, academic medical centers, and regional hospitals needing turn-key fill finish and packaging services.

Strong Backing Pharmalucence is part of Sun Pharma, providing access to larger corporate resources, regulatory support, and potential cross selling across a global radiopharma portfolio. The backing enables scale up investments, stable supply chains, and potential collaboration with Sun distribution networks to reach broader markets.

Regional Advantage Strategic location in Billerica, Massachusetts offers proximity to major Northeast academic medical centers, hospitals, and research institutions, enabling closer collaboration with imaging departments and nuclear medicine programs. The regional footprint enhances the ability to secure regional contracts for consistent radiopharmaceutical supply and timely distribution.

Portfolio Growth Portfolio focuses on seven radiopharmaceuticals including MDP, Pyrophosphate, DTPA, Disofenin, Mebrofenin, Sulfur Colloid, and Sestamibi, positioning Pharmalucence as a key supplier for nuclear medicine imaging needs. There is growth potential to broaden into additional radiopharmaceuticals or new formulation lines, especially leveraging Sun Pharma resources for pediatric and specialty markets. This combination offers opportunities to cross sell to imaging centers, hospitals, and academic partners seeking diverse radiopharma options.